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Abstract 
 
Introduction   
There is increasingly strong evidence that Human Papilloma Virus (HPV) is a risk 
factor for the development of oropharyngeal cancer. Evidence for a similar role in 
oral cancer (OSCC) is not as clear. Furthermore, it is also uncertain whether HPV 
may have an etiologic role in the development of oral epithelial dysplasia (OED) or its 
transformation to OSCC. Reported prevalence rates of HPV infection in oral 
premalignant lesions range from 0 to 100%. A recent meta-analysis estimates the 
prevalence of high-risk serotypes HPV16/18 in oral premalignant lesions and OSCC 
to be around 25%. Despite this being three times higher than was found in normal 
oral mucosa, it does not imply a causal relationship. Furthermore, very few studies 
have examined the prognostic significance of HPV positivity in the development of 
OSCC from oral premalignant lesions. Those that have either include cases without 
OED, or have very small numbers. This has led to conflicting results. 
 
Aims   
We aimed to examine the ability of p16INK4a protein expression, a surrogate marker of 
HPV infection, to predict malignant progression in a large cohort of patients with 
OED. 
 
Methods   
A cohort of 148 cases with a range of severity of OED, as defined by the WHO 
grading system was compiled. As well as histological grade, other clinical factors 
were collated on each case. Immunohistochemical analysis was performed on 4μm 
sections using a well validated and reproducible mouse monoclonal antibody 
directed against p16INK4a. Slides were double scored independently by two trained 
observers using a scoring system that considered both the intensity and proportion of 
cells stained. Univariate analyses using both logistic and Cox regression models (the 
latter also giving a time to event analysis) were performed. 
 
Results   
39 of the 148 cases progressed to cancer. 10 of the 148 cases (15%) had a p16INK4a 
score, which would indicate HPV positivity. Whereas a high grade of dysplasia (p= 
0.0002) and lesion morphology (p=0.03) were found to be prognostic of malignant 
progression, sex, anatomical location, smoking and alcohol status were not. p16INK4a 
score was not demonstrated to be a prognostic factor in this cohort (p=0.29). This did 
not change with a time to event analysis (p=0.24). 
 
Conclusion   
Very few studies have assessed the etiological role of HPV in OSCC development 
from dysplastic lesions. Despite the increased prevalence of HPV in OED compared 
to normal oral mucosa, our study, using the largest cohort of OED cases to examine 
this etiological role, was unable to demonstrate a prognostic ability for p16INK4a. 
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Introduction 
 
The role of the human papilloma virus (HPV) in the pathogenesis of oropharyngeal 
carcinoma (OPC) is now well established1-4. However, the aetiological role of HPV 
infection in the development of cancers of the oral cavity is currently not as clear.  
 
OSCC is thought to arise as a result of the accumulation of progressive genomic 
instability and consequent histological atypia5. This sometimes presents as oral 
epithelial dysplasia (OED). As only around 12% of OED lesions will undergo 
malignant transformation, it is termed a potentially malignant disorder6. The role of 
HPV in the development of OED and its transition from potentially malignant disorder 
to invasive disease is unclear. Several studies have examined the prevalence of 
HPV in oral potentially malignant lesions. A recent meta-analysis estimated HPV-
16/18 to be 3 times more common in dysplastic lesions (OR, 3.29; 95% CI, 1.95–
5.53) and cancers OR, 3.43; 95% CI, 2.07– 5.69) than in normal mucosal biopsies7. 
A second meta-analysis demonstrated an even higher association, with OED lesions 
5 times more likely to be HPV positive than normal mucosa (OR = 5.10; 95% CI: 
2.03–12.80)8. Yet, recent large studies show that only a small number of oral cancers 
are HPV positive, which is contradictory to what might be expected. Despite this, 
there have been few studies examining the prognostic role of HPV infection in the 
development of OSCC from potentially malignant lesions. These few studies report 
conflicting results.  
 
The aim of this study was to examine p16INK4a protein expression, a surrogate marker 
of HPV infection, to investigate if it was a prognostic marker of malignant progression 
in a large cohort of patients with OED. 
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Methods 
This study has been reported according to the REporting recommendations for 
tumour MARKer prognostic studies guidelines (REMARK)9. 
 
Cohort 
Archived tissue specimens from patients with OED biopsied between 1996 and 2008 
were identified from the pathology databases of University Hospital Coventry and 
Warwick, George Eliot Hospital Nuneaton, University Hospital Birmingham, 
Birmingham Dental Hospital and the University of Leeds. Inclusion required patients 
to be over 18 years of age at the time of biopsy, have a diagnosis of OED made by 
grading using the WHO classification and a minimum follow-up for non-transformed 
cases of 12 months. Any cases positive for fungi or Candida on diastase-resistant 
Periodic Acid Schiff (dPAS) staining were excluded from the study, as were cases 
diagnosed with lichenoid inflammation with atypia and proliferative verrucous 
leukoplakia. Further exclusions were made of cases that had previously been 
diagnosed with head and neck cancer, or had transformed to cancer within 3 months 
of diagnosis of OED. Potential risk factors such as age, gender, anatomical site, 
lesion morphology and smoking/alcohol history were recorded where possible and 
used as candidate variables in the prognostic model along with p16INK4a. 
 
Immunohistochemistry 
4μm sections were taken from Formalin-Fixed Paraffin-Embedded (FFPE) tissue 
blocks and a tissue microarray (TMA) constructed from a small number of the cohort. 
We have previously demonstrated near perfect agreement between scoring of TMA 
and whole sections with this and other biomarkers in OED10. Sections were 
deparaffinised for 10 minutes in xylene before rehydration in graded alcohol and 
distilled water. All sections underwent heat-induced epitope retrieval for 20 minutes 
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in citrate buffers at pH 6. The Novocastra™ Polymer Detection System was used 
with endogenous peroxidase activity blocked for 20 minutes with 3% hydrogen 
peroxide, followed by 30 minutes incubation with 0.4% Casein in phosphate-buffered 
saline. Sections were incubated overnight at 4°C in 1:5 concentration primary 
antibody (CINtec® monoclonal mouse antibody clone E6H4T directed to human 
p16INK4a protein, mtm laboratories AG, Germany). Sections were then exposed to 30 
minutes in post primary block and 30 minutes in NovoLink™ Polymer. Sections were 
finally incubated with the substrate/chromogen, 3,3’ - diaminobenzidine (DAB), 
before counterstaining with Haematoxylin. A case of oropharyngeal carcinoma with 
diffuse strong p16INK4a staining throughout was used as a positive control. 
 
Histological assessment of immunocytochemistry 
Two trained observers from the same institution scored slides independently, with 
consensus scoring in all cases where there was disagreement.  A scoring system 
that considered both the intensity and proportion of cells stained was used. Intensity 
of staining was scored on a 4 point scale: 0, negative (No staining); 1, weakly 
positive staining; 2, moderately positive staining; and 3, strongly positive staining. 
The proportion of cells stained was also scored on a 4-point scale: 1 (<25% of cells 
stained); 2 (25-50% of cells stained); 3 (51-75% of cells stained); 4 (>75% cells 
stained). These two scores were multiplied to give an overall score of 0 – 12 for each 
case. Only cases scoring >9 were considered positive. 
 
Statistical analysis 
The strength of agreement for immunohistochemical scoring between the two raters 
was assessed using both kappa (κ) and intraclass correlation coefficients (ICCC). 
ICCC has been suggested as superior in assessing agreement in this setting, 
however kappa scores were also calculated to allow comparison with other studies11. 
Agreement was interpreted using well accepted standards12,13. The ability of p16INK4a 
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or clinical factors to predict progression was calculated initially using a univariate 
logistic regression analysis. The primary outcome was progression to cancer. 
p16INK4a  was handled as a binary variable, with cases scoring <12 considered 
negative for the marker. Clinical factors were analysed as categorical variables in the 
following way: gender (male, female), Age (≤50, >50), smoker (Never, ex and 
current), alcohol (None, <21 units, >21 units) morphology (white patch, speckled 
red/white, red patch, ulcer and mass), site (tongue, floor of mouth, palate, buccal, 
retromolar) and histological grade (mild, moderate, severe, carcinoma in situ). 
Listwise deletion was used to handle missing data, whereby any cases with missing 
data relevant to that particular analysis were excluded. A Kaplan Meier survival 
analysis was subsequently performed to assess the effect of time on this prognostic 
ability, expressed as oral cancer free survival. Differences between oral cancer free 
survival curves were calculated using a Log-rank (Mantel-Cox) test with significance 
defined as p<0.05. Consensus scores were used for the p16INK4a analyses. 
Calculations were performed using SPSS version 19.0 for Mac; SPSS Inc., Chicago, 
IL, USA and SAS version 9.2.  
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Results 
Cohort characteristics 
148 cases of OED were included in the analysis. The cohort comprised 72 females 
(mean age 62, SD=14) and 76 males (mean age 60, SD=13). 69 cases (47%) were 
graded as mild, 50 (24%) as moderate, 27 (18%) as severe and 2 (1%) as carcinoma 
in situ. Median follow-up time was 42 months, (3 – 156 months) with 39 cases 
undergoing malignant transformation (26%). Further clinical characteristics are 
summarized in Table 1. 
 
Immunohistochemistry 
Excellent agreement was demonstrated between the two raters when scoring 
p16INK4a. This was consistent for both the intensity of staining and proportion of cells 
scored (κ=0.85, 0.86; ICCC= 0.93,0.94 respectively). 10 cases (7%) demonstrated 
positivity for p16INK4a protein on immunohistochemical staining. 4 of these 10 cases 
with positive p16INK4a staining progressed to cancer. 86 cases (58%) demonstrated 
no immunohistochemical staining for p16INK4a protein. A further 52 cases (35%) 
exhibited a variable pattern of staining for p16INK4a, with none of these cases meeting 
the criteria for p16INK4a positivity. Examples of each staining pattern are shown in 
figure 1. 
 
Prognostic markers of malignant progression 
p16INK4a score was not demonstrated to be a prognostic factor for malignant 
transformation in this cohort (p=0.29). This did not change even when performing a 
time to event analysis (hazard ratio 1.86; 95% CI 0.66, 5.3, p=0.24 figure 2). While a 
high grade of dysplasia (p= 0.0002) and lesion morphology (p=0.03) were found to 
be prognostic of malignant progression on univariate analysis, gender, anatomical 
location, smoking and alcohol status were not. On multivariate analysis, only 
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histological grade remained an independent predictor of malignant progression (HR 
1.64; 95% CI 1.12, 2.40, p=0.01). 
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Discussion 
Our study, the largest multi-center cohort to examine the prognostic role of a 
surrogate marker of HPV oncoprotein expression in OED, has revealed positivity to 
occur in only a small proportion of OED lesions. Furthermore, p16INK4a positivity 
demonstrated no evidence of a prognostic ability to predict malignant progression in 
OED. 
 
The relatively low rate of p16INK4a positivity in this cohort may be explained by our use 
of high intensity and proportion scores before assigning a case this status. This is in 
keeping with previously proposed classifications by Weinberger and supported by 
diagnostic algorithms proposed by Robinson et al14,15.In our study, other known risk 
factors such as smoking and alcohol intake were not prognostic, with only a high 
histopathological grade of dysplasia significantly predicted progression in this cohort, 
(p= 0.0002).  
 
Several studies have examined the prevalence rates of HPV infection in oral 
premalignant lesions. These have been summarized in a recent systematic review8. 
956 cases of oral potentially malignant disorders (OPMD) and 675 controls were 
included in the analysis. In all 19 cross sectional studies, HPV was seen in a higher 
proportion of the OPMD groups than in the controls (OR 3.87 (95% CI: 2.87–5.21). 
This association was even more significant with a subgroup analysis of cases of 
OED (OR 5.10; 95% CI: 2.03–12.80). These findings were confirmed in a second 
systematic review7. While most studies have used polymerase chain reaction (PCR) 
or in-situ hybridization (ISH), for the detection of HPV DNA, detection of p16INK4a 
protein overexpression by immunohistochemistry has also been shown to be a 
surrogate marker of HPV infection16-19.  
 
Detection of HPV DNA does not necessarily confirm the presence of active infection 
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however20. Furthermore, cross sectional studies do not allow the assumption to be 
made that detection of HPV DNA has any prognostic significance. To date, few 
longitudinal studies have examined the prognostic significance of the increased 
incidence of HPV infection in OPMD, and those that have report conflicting results. 
Nielsen et al reported HPV to be a likely cofactor in OSCC development, as 100% of 
the patients developing cancers were HPV positive21. However, this was only in 3 
patients, and the cohort of 49 OPMD contained a mixture of cases with and without 
dysplasia. Montebugnoli et al demonstrated p16INK4a positivity in 9/20 OPMD cases 
progressing to cancer22. Once again, the numbers were small and not all the cases 
progressing to cancer had preceding dysplasia. Furthermore, only 5% of cells were 
required to be stained for cases to be considered positive. No prognostic role for 
HPV was found in a large cohort of oral leukoplakias by Yang et al23. 11/167 cases 
progressed to malignancy, with 5 of these 11 cases being positive for HPV DNA. Yet 
only 45% of this cohort had dysplasia, and p16INK4a status was not examined.  
 
Limitations of the study 
This was a retrospectively collected cohort. Prospective collection, with more cases 
and longer follow-up would be favorable for validation of these findings. This study 
has also not correlated the detection of p16INK4a protein with HPV DNA and so a 
proportion of cases with p16INK4a positivity may not be due to HPV infection.  
However, this would further confirm our findings that p16INK4a positivity appears to 
have no prognostic role in this situation. Despite being one of the largest cohorts 
reported in the literature, a small chance of a type II error exists, due to small 
subgroup sizes. 
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Conclusion 
We have found no evidence that p16INK4a expression is able to predict malignant 
progression in cases of OED. Its use as a biomarker in helping to stratify the 
malignant potential of patients with OED cannot therefore be justified.  
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Table 1: Clinical characteristics of patient cohort and univariate analysis of risk 
factors for malignant transformation 
 
 
  Number  
(%) 
Logistic 
regression 
(p value) 
Smoking status at biopsy 
Current  69 (47) 
0.29 
Ex 9 (6) 
Non 47 (32) 
Unknown 23 (15) 
Alcohol consumption at 
biopsy 
 >28 Units/week 23 (15) 
0.61 
<28 Units/week 58 (40) 
None 44 (30) 
Unknown 23 (15) 
Morphology of lesion 
White patch 94 (63) 
0.03 
Red patch 15 (10) 
Speckled patch 13 (9) 
Ulcer 22 (15) 
Lump 4 (3) 
Site of lesion 
Tongue 69 (47) 
0.73 
Floor of mouth 20 (13) 
Palate 18 (12) 
Buccal 38 (26) 
Retromolar 3 (2) 
Gender 
Male 76 (51%) 
0.14 
Female 72 (49%) 
p16INK4a Positive 10 (7%) 0.29 
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Figure 1: Variability in p16INK4a expression in oral epithelial dysplasia. a) No staining; 
b) staining score of 2; c) Staining score of 6; d) Positive staining with a score of 12 
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Figure 2: Kaplan-Meier survival analysis curve demonstrating differences in oral 
cancer free survival between p16INK4a positive and negative groups. 
  
 16 
References 
 
 
 
1. Hausen zur H. Papillomaviruses and cancer: from basic studies to clinical 
application. Nat Rev Cancer. 2002 May;2(5):342–50.  
2. Mehanna H, Jones TM, Gregoire V, Ang KK. Oropharyngeal carcinoma 
related to human papillomavirus. BMJ. 2010 ed. 2010;340:c1439.  
3. Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, et al. 
Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in 
Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 
2009 Jul 15;125(2):362–6.  
4. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. 
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the 
United States. J Clin Oncol. 2011 Nov 8;29(32):4294–301.  
5. Califano J, der Riet van P, Westra W, Nawroz H, Clayman G, Piantadosi S, et 
al. Genetic progression model for head and neck cancer: implications for field 
cancerization. Cancer Res. 1996 Jun 1;56(11):2488–92.  
6. Mehanna HM, Rattay T, Smith J, McConkey CC. Treatment and follow-up of 
oral dysplasia - a systematic review and meta-analysis. Head Neck. 2009 
Dec;31(12):1600–9.  
7. Jayaprakash V, Reid M, Hatton E, Merzianu M, Rigual N, Marshall J, et al. 
Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity 
and oropharynx: A meta-analysis, 1985-2010. Oral Oncol. 2011 Aug 2.  
8. Syrjänen S, Lodi G, Bültzingslöwen von I, Aliko A, Arduino P, Campisi G, et al. 
Human papillomaviruses in oral carcinoma and oral potentially malignant 
disorders: a systematic review. Oral Dis. 2011 Apr;17 Suppl 1:58–72.  
9. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. 
REporting recommendations for tumour MARKer prognostic studies 
(REMARK). Br J Cancer. 2005 Aug 22;93(4):387–91.  
10. Nankivell PC, Williams H, Bartlett JMS, Mehanna H. Validation of tissue 
microarrays in oral epithelial dysplasia using a novel virtual-array technique. J 
Clin Pathol. 2012 Dec;65(12):1084–7.  
11. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, et 
al. Observer variation in immunohistochemical analysis of protein expression, 
time for a change? Histopathology. 2006 Jun;48(7):787–94.  
12. Landis JR, Koch GG. The measurement of observer agreement for categorical 
data. Biometrics. 1977 ed. 1977 Mar;33(1):159–74.  
13. Carrasco JL, Jover L. Estimating the generalized concordance correlation 
coefficient through variance components. Biometrics. 2003 Dec;59(4):849–58.  
14. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Sasaki C, et al. 
Prognostic significance of p16 protein levels in oropharyngeal squamous cell 
 17 
cancer. Clin Cancer Res. 2004 Sep 1;10(17):5684–91.  
15. Robinson M, Sloan P, Shaw R. Refining the diagnosis of oropharyngeal 
squamous cell carcinoma using human papillomavirus testing. Oral Oncol. 
2010 Jul;46(7):492–6.  
16. Klussmann JP, Gültekin E, Weissenborn SJ, Wieland U, Dries V, Dienes HP, 
et al. Expression of p16 protein identifies a distinct entity of tonsillar 
carcinomas associated with human papillomavirus. Am J Pathol. 2003 
Mar;162(3):747–53.  
17. Cunningham LL, Pagano GM, Li M, Tandon R, Holm SW, White DK, et al. 
Overexpression of p16INK4 is a reliable marker of human papillomavirus-
induced oral high-grade squamous dysplasia. Oral Surg Oral Med Oral Pathol 
Oral Radiol Endod. 2006 Jul;102(1):77–81.  
18. Fregonesi PAG, Teresa DB, Duarte RA, Neto CB, de Oliveira MRB, Soares 
CP. p16(INK4A) immunohistochemical overexpression in premalignant and 
malignant oral lesions infected with human papillomavirus. J. Histochem. 
Cytochem. 2003 Oct;51(10):1291–7.  
19. Angiero F, Gatta LB, Seramondi R, Berenzi A, Benetti A, Magistro S, et al. 
Frequency and role of HPV in the progression of epithelial dysplasia to oral 
cancer. Anticancer Res. 2010 Sep;30(9):3435–40.  
20. Ha PK, Califano JA. The role of human papillomavirus in oral carcinogenesis. 
Crit Rev Oral Biol Med. 2004;15(4):188–96.  
21. Nielsen H, Norrild B, Vedtofte P, Prætorius F, Reibel J, Holmstrup P. Human 
papillomavirus in oral premalignant lesions. Eur J Cancer, B, Oral Oncol. 1996 
Jul;32B(4):264–70.  
22. Montebugnoli L, Cervellati F, Cocchi R, Farnedi A, Pennesi MG, Flamminio F, 
et al. Immunohistochemical expression of p16(INK4A) protein as a helpful 
marker of a subset of potentially malignant oral epithelial lesions: study on a 
series with long-term follow-up. Histopathology. 2010 Oct;57(4):528–34.  
23. Yang S-W, Lee Y-S, Chen T-A, Wu C-J, Tsai C-N. Human papillomavirus in 
oral leukoplakia is no prognostic indicator of malignant transformation. Cancer 
Epidemiol. 2009 Aug;33(2):118–22.  
 
